Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Remdesivir (GS-5734) is an investigational nucleotide analog...
| Class:Id | Summation:9680490 |
|---|---|
| _displayName | Remdesivir (GS-5734) is an investigational nucleotide analog... |
| _timestamp | 2021-10-08 13:41:28 |
| created | [InstanceEdit:9680494] Jassal, Bijay, 2020-03-27 |
| literatureReference | [LiteratureReference:9680471] Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses [LiteratureReference:9680275] Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease |
| modified | [InstanceEdit:9681847] Jassal, Bijay, 2020-04-06 [InstanceEdit:9684395] Jassal, Bijay, 2020-04-21 [InstanceEdit:9686896] Jassal, Bijay, 2020-05-05 [InstanceEdit:9687387] Jassal, Bijay, 2020-05-07 [InstanceEdit:9687409] Jassal, Bijay, 2020-05-07 [InstanceEdit:9689382] Jassal, Bijay, 2020-05-19 [InstanceEdit:9755458] Stephan, Ralf, 2021-10-08 |
| text | Remdesivir (GS-5734) is an investigational nucleotide analogue drug that was developed for its broad spectrum antiviral potential against Ebola and Marburg virus activity (Siegel et al. 2017). It targets and inhibits viral RNA-dependent RNA polymerase (nsp12, RdRP), the key component of the replication transcription complex (RTC) (Agostini et al. 2018, Brown et al. 2019, Gordon et al. 2020). Remdesivir is being investigated for potential antiviral activity against SARS-CoV-2 by targeting viral replication (Agostini et al. 2018). Gordon et al. demonstrate remdesivir possesses broad antiviral activity against RNA viruses, including SARS-CoV, MERS-CoV and SARS-CoV-2 in-vitro (Gordon et al. 2020b). It could prevent asymptomatic, mild or moderate COVID-19 cases from progressing to severe disease (clinical trials NCT04252664, NCT04257656) but results so far in infected people have been mixed. Molnupiravir (EIDD-2801) is an isopropylester prodrug of the ribonucleoside analogue N4-hydroxycytidine (NHC, EIDD-1931) that shows broad spectrum antiviral activity against various RNA viruses including Ebola, Influenza and CoV (Toots et al. 2019). NHC acts as a competitive alternative substrate for virally encoded RNA-dependent RNA polymerases. NHC was shown to inhibit multiple genetically-distinct Bat-CoV viruses in human primary epithelial cells without affecting cell viability. Prophylactic/therapeutic oral administration of NHC reduced lung titers and prevented acute lung failure in C57B/6 mice infected with CoV. The potency of NHC against multiple coronaviruses, its therapeutic efficacy, and oral bioavailability in vivo, all highlight its potential as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses (Sheahan et al. 2020). The clinical trial NCT04575584 was terminated prematurely for ethical reasons because molnupiravir reached its endpoint of effectiveness against COVID-19. |
| (summation) | [Reaction:9680262] SARS coronavirus gRNA:RTC:RNA primer binds RTC inhibitors [Homo sapiens] [Reaction:9687388] SARS-CoV-1 gRNA:RTC:nascent RNA minus strand binds RTC inhibitors [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Remdesivir (GS-5734) is an investigational nucleotide analog... (9680490)
